Julia A Bielicki1, Wolfgang Stöhr2, Sam Barratt2, David Dunn2, Nishdha Naufal2, Damian Roland3,4, Kate Sturgeon2, Adam Finn5, Juan Pablo Rodriguez-Ruiz6, Surbhi Malhotra-Kumar6, Colin Powell7,8, Saul N Faust9,10, Anastasia E Alcock11, Dani Hall11,12, Gisela Robinson13, Daniel B Hawcutt14,15, Mark D Lyttle16,17, Diana M Gibb2, Mike Sharland1. 1. Pediatric Infectious Diseases Research Group, Medical Research Council Clinical Trial Unit at University College London, Institute for Infection and Immunity, St George's University of London, London, United Kingdom. 2. Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom. 3. Pediatric Emergency Medicine Leicester Academic (PEMLA) Group, Emergency Department, Leicester, United Kingdom. 4. SAPPHIRE Group, University of Leicester, Department of Health Sciences, Leicester, United Kingdom. 5. Bristol Children's Vaccine Centre, Schools of Population Sciences and Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom. 6. Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium. 7. Emergency Medicine, Sidra Medical and Research Center, Doha, Qatar. 8. Division of Population Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom. 9. National Institute for Health Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. 10. Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, United Kingdom. 11. Pediatric Emergency Medicine, Evelina Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. 12. Pediatric Emergency Medicine, Children's Health Ireland at Crumlin, Ireland. 13. Pediatric Emergency Medicine, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom. 14. Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom. 15. Pediatric Medicines Research Unit, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom. 16. Emergency Department, Bristol Royal Hospital for Children, Bristol, United Kingdom. 17. Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom.
Abstract
Importance: The optimal dose and duration of oral amoxicillin for children with community-acquired pneumonia (CAP) are unclear. Objective: To determine whether lower-dose amoxicillin is noninferior to higher dose and whether 3-day treatment is noninferior to 7 days. Design, Setting, and Participants: Multicenter, randomized, 2 × 2 factorial noninferiority trial enrolling 824 children, aged 6 months and older, with clinically diagnosed CAP, treated with amoxicillin on discharge from emergency departments and inpatient wards of 28 hospitals in the UK and 1 in Ireland between February 2017 and April 2019, with last trial visit on May 21, 2019. Interventions: Children were randomized 1:1 to receive oral amoxicillin at a lower dose (35-50 mg/kg/d; n = 410) or higher dose (70-90 mg/kg/d; n = 404), for a shorter duration (3 days; n = 413) or a longer duration (7 days; n = 401). Main Outcomes and Measures: The primary outcome was clinically indicated antibiotic re-treatment for respiratory infection within 28 days after randomization. The noninferiority margin was 8%. Secondary outcomes included severity/duration of 9 parent-reported CAP symptoms, 3 antibiotic-related adverse events, and phenotypic resistance in colonizing Streptococcus pneumoniae isolates. Results: Of 824 participants randomized into 1 of the 4 groups, 814 received at least 1 dose of trial medication (median [IQR] age, 2.5 years [1.6-2.7]; 421 [52%] males and 393 [48%] females), and the primary outcome was available for 789 (97%). For lower vs higher dose, the primary outcome occurred in 12.6% with lower dose vs 12.4% with higher dose (difference, 0.2% [1-sided 95% CI -∞ to 4.0%]), and in 12.5% with 3-day treatment vs 12.5% with 7-day treatment (difference, 0.1% [1-sided 95% CI -∞ to 3.9]). Both groups demonstrated noninferiority with no significant interaction between dose and duration (P = .63). Of the 14 prespecified secondary end points, the only significant differences were 3-day vs 7-day treatment for cough duration (median 12 days vs 10 days; hazard ratio [HR], 1.2 [95% CI, 1.0 to 1.4]; P = .04) and sleep disturbed by cough (median, 4 days vs 4 days; HR, 1.2 [95% CI, 1.0 to 1.4]; P = .03). Among the subgroup of children with severe CAP, the primary end point occurred in 17.3% of lower-dose recipients vs 13.5% of higher-dose recipients (difference, 3.8% [1-sided 95% CI, -∞ to10%]; P value for interaction = .18) and in 16.0% with 3-day treatment vs 14.8% with 7-day treatment (difference, 1.2% [1-sided 95% CI, -∞ to 7.4%]; P value for interaction = .73). Conclusions and Relevance: Among children with CAP discharged from an emergency department or hospital ward (within 48 hours), lower-dose outpatient oral amoxicillin was noninferior to higher dose, and 3-day duration was noninferior to 7 days, with regard to need for antibiotic re-treatment. However, disease severity, treatment setting, prior antibiotics received, and acceptability of the noninferiority margin require consideration when interpreting the findings. Trial Registration: ISRCTN Identifier: ISRCTN76888927.
Importance: The optimal dose and duration of oral amoxicillin for children with community-acquired pneumonia (CAP) are unclear. Objective: To determine whether lower-dose amoxicillin is noninferior to higher dose and whether 3-day treatment is noninferior to 7 days. Design, Setting, and Participants: Multicenter, randomized, 2 × 2 factorial noninferiority trial enrolling 824 children, aged 6 months and older, with clinically diagnosed CAP, treated with amoxicillin on discharge from emergency departments and inpatient wards of 28 hospitals in the UK and 1 in Ireland between February 2017 and April 2019, with last trial visit on May 21, 2019. Interventions: Children were randomized 1:1 to receive oral amoxicillin at a lower dose (35-50 mg/kg/d; n = 410) or higher dose (70-90 mg/kg/d; n = 404), for a shorter duration (3 days; n = 413) or a longer duration (7 days; n = 401). Main Outcomes and Measures: The primary outcome was clinically indicated antibiotic re-treatment for respiratory infection within 28 days after randomization. The noninferiority margin was 8%. Secondary outcomes included severity/duration of 9 parent-reported CAP symptoms, 3 antibiotic-related adverse events, and phenotypic resistance in colonizing Streptococcus pneumoniae isolates. Results: Of 824 participants randomized into 1 of the 4 groups, 814 received at least 1 dose of trial medication (median [IQR] age, 2.5 years [1.6-2.7]; 421 [52%] males and 393 [48%] females), and the primary outcome was available for 789 (97%). For lower vs higher dose, the primary outcome occurred in 12.6% with lower dose vs 12.4% with higher dose (difference, 0.2% [1-sided 95% CI -∞ to 4.0%]), and in 12.5% with 3-day treatment vs 12.5% with 7-day treatment (difference, 0.1% [1-sided 95% CI -∞ to 3.9]). Both groups demonstrated noninferiority with no significant interaction between dose and duration (P = .63). Of the 14 prespecified secondary end points, the only significant differences were 3-day vs 7-day treatment for cough duration (median 12 days vs 10 days; hazard ratio [HR], 1.2 [95% CI, 1.0 to 1.4]; P = .04) and sleep disturbed by cough (median, 4 days vs 4 days; HR, 1.2 [95% CI, 1.0 to 1.4]; P = .03). Among the subgroup of children with severe CAP, the primary end point occurred in 17.3% of lower-dose recipients vs 13.5% of higher-dose recipients (difference, 3.8% [1-sided 95% CI, -∞ to10%]; P value for interaction = .18) and in 16.0% with 3-day treatment vs 14.8% with 7-day treatment (difference, 1.2% [1-sided 95% CI, -∞ to 7.4%]; P value for interaction = .73). Conclusions and Relevance: Among children with CAP discharged from an emergency department or hospital ward (within 48 hours), lower-dose outpatient oral amoxicillin was noninferior to higher dose, and 3-day duration was noninferior to 7 days, with regard to need for antibiotic re-treatment. However, disease severity, treatment setting, prior antibiotics received, and acceptability of the noninferiority margin require consideration when interpreting the findings. Trial Registration: ISRCTN Identifier: ISRCTN76888927.
Authors: John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson Journal: Clin Infect Dis Date: 2011-08-31 Impact factor: 9.079
Authors: Femke de Velde; Brenda C M de Winter; Birgit C P Koch; Teun van Gelder; Johan W Mouton Journal: J Antimicrob Chemother Date: 2016-06-20 Impact factor: 5.790
Authors: Matthew P Kronman; Adam L Hersh; Rui Feng; Yuan-Shung Huang; Grace E Lee; Samir S Shah Journal: Pediatrics Date: 2011-02-14 Impact factor: 7.124
Authors: Shabir A Madhi; Philippe De Wals; Carlos G Grijalva; Keith Grimwood; Ronald Grossman; Naruhiko Ishiwada; Ping-Ing Lee; Cristiana Nascimento-Carvalho; Hanna Nohynek; Katherine L O'Brien; Anne Vergison; Joanne Wolter Journal: Pediatr Infect Dis J Date: 2013-03 Impact factor: 2.129
Authors: Amy-Sarah Ginsburg; Tisungane Mvalo; Evangelyn Nkwopara; Eric D McCollum; Melda Phiri; Robert Schmicker; Jun Hwang; Chifundo B Ndamala; Ajib Phiri; Norman Lufesi; Susanne May Journal: N Engl J Med Date: 2020-07-02 Impact factor: 91.245
Authors: Mark D Lyttle; Julia A Bielicki; Sam Barratt; David Dunn; Adam Finn; Lynda Harper; Pauline Jackson; Colin V E Powell; Damian Roland; Wolfgang Stohr; Kate Sturgeon; Mandy Wan; Paul Little; Saul N Faust; Julie Robotham; Alastair D Hay; Diana M Gibb; Mike Sharland Journal: BMJ Open Date: 2019-05-22 Impact factor: 2.692
Authors: Jeffrey M Pernica; Stuart Harman; April J Kam; Redjana Carciumaru; Thuva Vanniyasingam; Tyrus Crawford; Dale Dalgleish; Sarah Khan; Robert S Slinger; Martha Fulford; Cheryl Main; Marek Smieja; Lehana Thabane; Mark Loeb Journal: JAMA Pediatr Date: 2021-05-01 Impact factor: 16.193
Authors: Jan Y Verbakel; Ann Van den Bruel; Matthew Thompson; Richard Stevens; Bert Aertgeerts; Rianne Oostenbrink; Henriette A Moll; Marjolein Y Berger; Monica Lakhanpaul; David Mant; Frank Buntinx Journal: BMC Med Date: 2013-01-15 Impact factor: 8.775
Authors: Isabela R Marques; Izabela P Calvi; Sara A Cruz; Luana M F Sanchez; Isis F Baroni; Christi Oommen; Eduardo M H Padrao; Paula C Mari Journal: Eur J Pediatr Date: 2022-09-06 Impact factor: 3.860